MWNA
PDLI

Marshall Wace North America’s PDL BioPharma, Inc. PDLI Stock Holding History

Marshall Wace North America’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,311
Closed -$40K – 1771
2019
Q4 		$40K Buy
+12,311
New +$35.7K ﹤0.01% 1172
2018
Q2 		– Sell
-11,819
Closed -$35K – 1932
2018
Q1 		$35K Buy
+11,819
New +$32.3K ﹤0.01% 1389
2017
Q4 		– Sell
-88,446
Closed -$265K – 1811
2017
Q3 		$265K Buy
+88,446
New +$246K ﹤0.01% 1148

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace North America's PDLI Position: Q1 2020 in Review

Marshall Wace North America sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 12,311 shares — an estimated $40K sold.

Marshall Wace North America first reported a position in PDLI in Q3 2017 and held it in 3 quarters. The position peaked at $265K in Q3 2017. 133 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • Marshall Wace North America reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 12,311 PDL BioPharma, Inc. shares in Q1 2020, an estimated $40K.
  • Marshall Wace North America first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 3 quarters.
  • Marshall Wace North America's PDL BioPharma, Inc. position peaked at $265K in Q3 2017.
  • 133 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.